Zai Lab Limited
A biopharmaceutical company that develops and brings to market medicines for cancer, immunology, neuroscience, and infectious disease, with a presence in both China and the United States. Founded in 2014 by Dr. Samantha Du, often called the 'godmother of China's biotech industry,' it was built to bring global medical innovations to Chinese patients faster. Its name comes from the Chinese character 'zài' (在), meaning 'to be' or 'to exist' — a nod to being present in patients' lives.
American Depositary Receipt
Granted 3.00M · Sold 1.23M
Granted 10.0K · Sold 40.0K
Granted 81.1K · Bought 4.0K · Sold 7.9K
Granted 81.1K · Sold 2.0K
Granted 139.6K · Bought 25.0K · Sold 42.7K
Granted 730
Granted 33.2K
Granted 81.1K
Granted 82.3K · Bought 1.7K · Sold 5.0K
Granted 72.8K
Granted 132.4K · Sold 49.4K
Granted 270.5K · Sold 87.5K
Granted 80.7K · Sold 23.8K
Granted 3.7K
Granted 81.1K · Sold 53.6K
Granted 40.2K · Sold 7.8K
Granted 69.3K · Sold 39.6K
Granted 156.2K · Sold 123.3K
Granted 1.1K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Du YingChairperson & CEO, Director · 146 transactions | +15.4% | 1.19M | 3.00M | — | 1.23M |
| Fu TaoPresident & COO, Director · 19 transactions | -6.9% | 675.1Kas of Oct 2021 | 10.0K | — | 40.0K |
| Wirth PeterDirector · 8 transactions | +1088.9% | 416.1K | 81.1K | 4.0K | 7.9K |
| Diekman John DDirector · 7 transactions | +190.7% | 122.1K | 81.1K | — | 2.0K |
| Smiley Joshua LSee Remarks · 23 transactions | — | 117.6K | 139.6K | 25.0K | 42.7K |
| Liang YiCCO & President, Greater China · 1 transaction | +0.7% | 104.8Kas of Apr 2022 | 730 | — | — |
| Leung NisaDirector · 4 transactions | — | 96.3K | 33.2K | — | — |
| Moulder Leon O JrDirector · 5 transactions | +585.6% | 95.0K | 81.1K | — | — |
| Gaynor RichardDirector · 8 transactions | — | 79.0K | 82.3K | 1.7K | 5.0K |
| Vounatsos MichelDirector · 4 transactions | — | 72.8K | 72.8K | — | — |
| Reinhart HaraldSee Remarks · 43 transactions | +682.7% | 62.6Kas of Jun 2024 | 132.4K | — | 49.4K |
| Amado RafaelSee Remarks · 25 transactions | — | 57.0K | 270.5K | — | 87.5K |
| Morrison Scott WDirector · 6 transactions | — | 56.9K | 80.7K | — | 23.8K |
| Cho William Ki ChulChief Financial Officer · 3 transactions | +7.5% | 53.7Kas of Apr 2023 | 3.7K | — | — |
| Lis WilliamDirector · 12 transactions | +78.4% | 50.4K | 81.1K | — | 53.6K |
| Chen Kai-XianDirector · 6 transactions | +60.3% | 39.5Kas of Dec 2024 | 40.2K | — | 7.8K |
| Chen YajingChief Financial Officer · 42 transactions | — | 35.6K | 69.3K | — | 39.6K |
| Edmondson Frazor Titus IIIChief Legal Officer · 51 transactions | +31.5% | 30.3K | 156.2K | — | 123.3K |
| Sandler Alan B.Head of Global Dev., Oncology · 2 transactions | -3.4% | 29.0Kas of Apr 2022 | 1.1K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -1.68M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.